On Nov 07, major Wall Street analysts update their ratings for $Cencora (COR.US)$, with price targets ranging from $249 to $292.
BofA Securities analyst Allen Lutz maintains with a hold rating, and adjusts the target price from $245 to $255.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $263 to $290.
Wells Fargo analyst Steve Baxter maintains with a hold rating, and maintains the target price at $249.
Mizuho Securities analyst Ann Hynes maintains with a hold rating.
Baird analyst Dave Rodgers maintains with a buy rating, and adjusts the target price from $283 to $292.
Furthermore, according to the comprehensive report, the opinions of $Cencora (COR.US)$'s main analysts recently are as follows:
The company experienced a moderate operational outperformance, driven by robust results in the U.S. Healthcare sector, which was somewhat counterbalanced by weaker outcomes internationally.
The company delivered a robust report, provided positive guidance, and announced an intriguing deal with MSO in a new domain for distributors, specifically retina care specialists.
Here are the latest investment ratings and price targets for $Cencora (COR.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
